New Delhi: Patanjali Ayurved on Wednesday issued a press note stating that all the documents relating to the COVID-19 clinical trial were shared with the Union AYUSH ministry. “Now, there is no difference of opinions between Ayush ministry and Patanjali,” it said.
According to the statement, Patanjali Research Institute, Haridwar and NIMS University, Jaipur has jointly conducted “randomised placebo-controlled double-binded clinical trials on COVID-19 positive patients.” According to the release, the trial was approved by the Institutional Ethics Committee (IEC) and duly registered at Clinical Trial Registry India.
“In this trial, 95 patients (15-65 years’ age range, male-female both, asymptomatic, mild to moderate) participated on the written consent basis,” read the statement. Out of the 95 patients, 45 of them were treated with Patanjali medicines and the rest 50 were given placebo formulations. “The COVID-19 patient group that received Patanjali medicines showed 67% recovery in 3 days and 100% recovery in 7 days of treatments, that is, all 45 patients became COVID-19 negative,” the statement added.
The press statement also said that as per the Ayush ministry, Patanjali is allowed to manufacture and distribute its Divya Coronil Tablet, Divya SwasariVati, and Divya AnuTalia across India, as per the manufacturing licenses granted by State Licencing Authority, Ayurvedic and Unani services, Govt of Uttarakhand.
This press release comes a day after the chief executive officer of Patanjali, Acharya Balkrishna clarified that the company did not claim its newly-tested medicine Coronil would treat COVID-19. Stating that the medicine is only for immunity boosting, cough, fever, and allergic problems. Last week the claims by Patanjali that it had cured all COVID-19 patients within a week which triggered a row with the Union Ayush ministry directing the firm not to sell the drug.
Uttarakhand’s Ayurveda department stated that the firm had only applied for a licence to manufacture an “immunity booster” and not a cure for COVID-19. And with this press release, Patanjali clarifies that they are not promoting any “kit” for the treatment of COVID-19 but rather sharing the “successful trial” findings.